Literature DB >> 8287946

Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients.

R Escamilla1, M C Prevost, C Cariven, C Hermant, M Krempf, H Chap.   

Abstract

Our aim was to evaluate the quality of pulmonary surfactant, a nonspecific defence system, during the course of human immunodeficiency virus) infection. Protein and phospholipid composition were determined in 127 bronchoalveolar lavage (BAL) fluids from 89 HIV seropositive patients (54 acquired immune deficiency syndrome (AIDS), 35 non-AIDS) and 11 healthy controls. In all of the HIV BAL samples, biochemical abnormalities were found. In subjects with pulmonary infection or Kaposi's sarcoma, the phospholipid/protein ratio was decreased, mainly because of elevated protein levels (15.8 and 20, respectively, vs 7.2 mg.100 ml-1 for controls, p < 0.05). In subjects without obvious pulmonary involvement, phospholipid was decreased (1.3 +/- 0.2 vs 2.9 +/- 0.3 mg.100 ml-1 for controls, p < 0.001), whereas the protein was not altered. Phospholipid composition was also altered: the phosphatidylcholine percentage was decreased, whilst the other main phospholipids were increased. We conclude that the alveolar lining is altered, whatever the stage of HIV disease. In most patients, it results from an increase of vascular permeability, with an influx of serum proteins. However, changes in phospholipid composition suggest that, in some cases, surfactant is also altered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287946

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  1 in total

1.  Phosphatidylcholine Liposomes Down-Modulate CD4 Expression Reducing HIV Entry in Human Type-1 Macrophages.

Authors:  Federica De Santis; Ana Borrajo Lopez; Sara Virtuoso; Noemi Poerio; Patrizia Saccomandi; Tommaso Olimpieri; Leonardo Duca; Lucia Henrici De Angelis; Katia Aquilano; Marco Maria D'Andrea; Stefano Aquaro; Alessandra Borsetti; Francesca Ceccherini-Silberstein; Maurizio Fraziano
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.